<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="134373">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01754779</url>
  </required_header>
  <id_info>
    <org_study_id>032012-058</org_study_id>
    <secondary_id>R21DK097476-01</secondary_id>
    <nct_id>NCT01754779</nct_id>
  </id_info>
  <brief_title>Treatment for Calcium Phosphate Kidney Stone Disease</brief_title>
  <official_title>Pharmacological Therapy for Calcium Phosphate Urolithiasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
    <authority>United States: Institutional Review Board</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will examine in two studies whether citric acid or potassium citrate can
      reduce calcium phosphate saturation in urine of Calcium Phosphate stone formers.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Urinary calcium phosphate saturation</measure>
    <time_frame>2 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Calcium Phosphate Kidney Stones</condition>
  <arm_group>
    <arm_group_label>Calcium Phosphate stone formers without hypercalciuria</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In this double-blind, placebo-controlled, crossover study, each subject will undergo 3 phases, the order of which will be randomized by a simple randomization scheme. The 3 phases will be Placebo, Citric Acid, and Potassium Citrate. Each phase will be 1 week in duration, during which subjects will take assigned study medications. A 1-week washout period is imposed between phases.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Calcium Phosphate stone formers with hypercalciuria</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In this double-blind, placebo-controlled crossover study, each hypercalciuric CaP stone former will undergo 3 phases, the order of which will be randomized by a simple randomization scheme.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo for both aims.</description>
    <arm_group_label>Calcium Phosphate stone formers without hypercalciuria</arm_group_label>
    <arm_group_label>Calcium Phosphate stone formers with hypercalciuria</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Citric Acid</intervention_name>
    <arm_group_label>Calcium Phosphate stone formers without hypercalciuria</arm_group_label>
    <arm_group_label>Calcium Phosphate stone formers with hypercalciuria</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Potassium Citrate</intervention_name>
    <arm_group_label>Calcium Phosphate stone formers without hypercalciuria</arm_group_label>
    <arm_group_label>Calcium Phosphate stone formers with hypercalciuria</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indapamide</intervention_name>
    <description>Aim 2</description>
    <arm_group_label>Calcium Phosphate stone formers with hypercalciuria</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Aim 1

          -  Hypocitraturic CaP stone formers

          -  urine citrate &lt;320mg/d

          -  elevated pH as 24-hr urine pH above 6.40

          -  &gt;21 years

        Aim 2

          -  Hypercalciuric CaP stone formers

          -  24hr urine calcium &gt;250mg/d in women and &gt;300mg/d in men prior to indapamide use

          -  high pH as &gt;6.40 in the absence of urinary tract infection

          -  &gt;21 years
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naim M Maalouf, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reena John, RN</last_name>
    <phone>214-648-0399</phone>
    <email>Reena.John@utsouthwestern.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-8885</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naim M Maalouf, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>December 18, 2012</lastchanged_date>
  <firstreceived_date>December 14, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Naim Maalouf</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>calcium phosphate</keyword>
  <keyword>urolithiasis</keyword>
  <keyword>kidney stones</keyword>
  <keyword>hypercalciuria</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Calculi</mesh_term>
    <mesh_term>Kidney Calculi</mesh_term>
    <mesh_term>Nephrolithiasis</mesh_term>
    <mesh_term>Urolithiasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Indapamide</mesh_term>
    <mesh_term>Potassium Citrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
